Clearmind Advances CMND-100 Trial with Yale IRB Approval, Expanding Patient Recruitment
Event summary
- Yale IRB approval enables patient recruitment for Parts B and C of Clearmind's Phase I/II CMND-100 trial.
- Trial now active at Yale, Johns Hopkins, and Israeli medical centers.
- Part A of the trial reported positive safety results across 24 participants with no serious adverse events.
- CMND-100 demonstrated consistent safety profile across all dose cohorts.
The big picture
Clearmind's expansion into Yale University's IRB-approved trial sites marks a strategic acceleration in its Phase I/II clinical program for CMND-100, a non-hallucinogenic psychedelic-derived neuroplastogen. The move aligns with the broader industry trend of leveraging top-tier academic institutions to validate novel psychiatric treatments. The positive safety data from Part A positions Clearmind favorably in the competitive landscape of psychedelic therapeutics, particularly for alcohol use disorder, a market with significant unmet medical needs.
What we're watching
- Trial Execution
- The pace at which Clearmind can enroll and retain patients across its expanded trial sites will determine the timeline for Part B and C results.
- Regulatory Pathway
- Whether the positive safety data from Part A will translate into similar outcomes in Parts B and C, supporting CMND-100's path to potential FDA approval.
- Competitive Positioning
- How Clearmind's non-hallucinogenic approach differentiates it in the growing psychedelic therapeutics market, particularly for alcohol use disorder.